CRP and inflammatory myofibroblastic tumor: Approximately 15%–30% of IMT patients may experience systemic symptoms including unexplained fever, weight loss, anemia, thrombocytosis, polyclonal hyperglobulinemia, and elevated erythrocyte sedimentation rate (ESR), procalcitonin (PCT), and c-reactive protein (CRP) levels (Kerr et al., 2021).